OC
IDYA icon

Oppenheimer & Co’s IDEAYA Biosciences IDYA Stock Holding History

Oppenheimer & Co’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,942
Closed -$217K – 1478
2024
Q1 		$217K Buy
+4,942
New +$212K ﹤0.01% 1306

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Oppenheimer & Co's IDYA Position: Q2 2024 in Review

Oppenheimer & Co sold out of IDEAYA Biosciences (IDYA) in Q2 2024, closing a stake of 4,942 shares — an estimated $217K sold.

Oppenheimer & Co first reported a position in IDYA in Q1 2024 and held it in 1 quarter. The position peaked at $217K in Q1 2024. 199 funds tracked by Wall St. Rank hold IDYA as of Q2 2024.

  • Oppenheimer & Co reported no remaining IDEAYA Biosciences position as of Q2 2024 after selling out during the quarter.
  • Oppenheimer & Co sold 4,942 IDEAYA Biosciences shares in Q2 2024, an estimated $217K.
  • Oppenheimer & Co first reported a position in IDEAYA Biosciences in Q1 2024 and held it in 1 quarter.
  • Oppenheimer & Co's IDEAYA Biosciences position peaked at $217K in Q1 2024.
  • 199 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q2 2024.

Based on Oppenheimer & Co's 13F filing for Q2 2024, filed 8 Aug 2024.